1-6 of 6
Sheila J O'Connor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 − mantle cell lymphoma

David Martín-Garcia, Alba Navarro, Rafael Valdés-Mas, Guillem Clot, Jesús Gutiérrez-Abril, Miriam Prieto, Inmaculada Ribera-Cortada, Renata Woroniecka, Grzegorz Rymkiewicz, Susanne Bens, Laurence de Leval, Andreas Rosenwald, Judith A. Ferry, Eric D. Hsi, Kai Fu, Jan Delabie, Dennis Weisenburger, Daphne de Jong, Fina Climent, Sheila J. O’Connor, Steven H. Swerdlow, David Torrents, Sergi Beltran, Blanca Espinet, Blanca González-Farré, Luis Veloza, Dolors Costa, Estella Matutes, Reiner Siebert, German Ott, Leticia Quintanilla-Martinez, Elaine S. Jaffe, Carlos López-Otín, Itziar Salaverria, Xose S. Puente, Elias Campo, Sílvia Beà
Journal: Blood
Blood (2019) 133 (9): 940–951.
https://doi.org/10.1182/blood-2018-07-862151
Published: 2019
Includes: Supplemental data
Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 1884.
https://doi.org/10.1182/blood.V122.21.1884.1884
Published: 2013
Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 765.
https://doi.org/10.1182/blood.V122.21.765.765
Published: 2013
Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 34.
https://doi.org/10.1182/blood.V108.11.34.34
Published: 2006
Journal Articles

EBV Related Transformation Events in CLL.

Hazem A. Sayala, MD, Sheila J. O’Connor, PhD, Andrew S. Jack, PhD, Chetan Patalappa, Peter Hillmen, MD, PhD, Roger G. Owen, MD
Journal: Blood
Blood (2006) 108 (11): 4963.
https://doi.org/10.1182/blood.V108.11.4963.4963
Published: 2006
Journal Articles

Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.

Sheila J. O’Connor, PhD, Kathryn Turner, MSc, Sharon L. Barrans, PhD, Brad Dickinson, MSc, Andy C. Rawstron, PhD, Hazem Sayala, MD, Paul Moreton, MD, Roger G. Owen, MD, Andrew S. Jack, PhD, Peter Hillmen, PhD
Journal: Blood
Blood (2005) 106 (11): 2936.
https://doi.org/10.1182/blood.V106.11.2936.2936
Published: 2005